, Tracking Stock Market Picks
Enter Symbol:
Rating: CLVS
Neutral $28
down 60.00 %

Clovis Oncology Inc (NASDAQ: CLVS) downgraded to Neutral with price target $28 by Piper Jaffray

Monday,  Nov 16, 2015  12:25 PM ET by Kristen Bailey

The Piper Jaffray advised against investing in this stock and the price has fallen for a loss. The price fell from $73.61 on 06/06/2013 to $29.79 on 11/16/2015. Piper Jaffray downgraded
Clovis Oncology Inc (NASDAQ: CLVS) to Neutral with price target $28 with today's price of $29.79. Piper Jaffray rated Clovis Oncology Inc (NASDAQ: CLVS) to Overweight on 06/06/2013, when the price was $73.61. Clovis Oncology Inc's stock price lost 60% since then.
By following the previous Piper Jaffray's recommendation on CLVS, you would have lost 60% in 893 days.

Clovis Oncology, Inc. (Clovis) is a Development-stage Company. The Company is a Biopharmaceutical Company. The Company focuses on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company also focuses on the treatment of specific subsets of cancer populations. During the year ended December 31, 2010, the Company was in the process of developing three product candidates for which it holds global marketing rights: CO-101, a lipid-conjugated form of the anti-cancer drug gemcitabine; CO-1686, an oral epidermal growth factor receptor (EGFR) mutant-selective inhibitor and CO-338, a poly ADP (Adenosine Diphosphate)-ribose polymerase (PARP) inhibitor.

At Piper Jaffray, we understand there’s no substitute for relevant and timely research. That's why we provide: * fundamental and technical research * value-added investment ideas * market analysis With the information our research team provides, you’ll make better and more informed decisions for your portfolio.

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy